382

Search

Incuron, LLC

Russian Pharmaceutical Company Incuron, LLC was created in January 2010 by private mutual fund with high-risk (venture) investments «Bioprocess Capital Ventures» (onward «Fund») cooperative with American Public Company «Cleveland Biolabs, Inc.»

Incuron Announce Start of Phase 1 Trial for CBL0137

The trial is being conducted at five leading oncology centers in the Russian Federation. The primary objective of the study is to determine the maximum tolerated dose and dose limiting toxic

Incuron Announce CBL0102 Orphan Drug Status for Hepatocellular Carcinoma

A multi-center Phase I trial of CBL0102 is ongoing in the Russian Federation in patients with liver metastases of solid tumors of epithelial origin, or primary advanced hepatic carcinoma for

Incuron, LLC announces start of a phase Ib safety and tolerability trial for curaxin CBL0102 in patients with liver tumors of different etiology in Russia

The study is a multicenter open-label, dose escalation, Phase 1b safety and tolerability study in patients with liver metastases of solid tumor of epithelial origin, or primary advanced hepa

Latest news

Incuron Announce CBL0102 Orphan Drug Status for Hepatocellular Carcinoma

A multi-center Phase I trial of CBL0102 is ongoing in the Russian Federation in patients with liver

Cell Reports Publication Elucidates Role of FACT as Accelerator of Tumor Transformation and Potential Marker and Target of Aggressive Cancers

Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fund and Clevel

Cell Reports Publication Elucidates Role of FACT as Accelerator of Tumor Transformation and Potential Marker and Target of Aggressive Cancers

Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fund and Clevel

Incuron Announce CBL0102 Orphan Drug Status for Hepatocellular Carcinoma

A multi-center Phase I trial of CBL0102 is ongoing in the Russian Federation in patients with liver

Incuron Announce Start of Phase 1 Trial for CBL0137

The trial is being conducted at five leading oncology centers in the Russian Federation. The primary

With the support of the innovation center Skolkovo

Aboute us

Incuron, LLC is a Russian Federation based joint venture founded in January 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures" (hereinafter "Fund"), and Cleveland BioLabs.

Incuron, LLC is developing an innovative pipeline of drugs to treat oncology and autoimmune disease for the global markets. Incuron's research and development operations include activities in both the Russian Federation and the U.S.

Video

You are here:   HomeHome